Article
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Cancer - 1 Jan 2020
Takahama Takayuki, Azuma Koichi, Shimokawa Mototsugu, Takeda Masayuki, Ishii Hidenobu, Kato Terufumi, Saito Haruhiro, Daga Haruko, Tsuboguchi Yuko, Okamoto Isamu, Otsubo Kohei, Akamatsu Hiroaki, Teraoka Shunsuke, Takahashi Toshiaki, Ono Akira, Ohira Tatsuo, Yokoyama Toshihide, Sakai Kazuko, Yamamoto Nobuyuki, Nishio Kazuto, Nakagawa Kazuhiko
Abstract excerpt
BACKGROUND: Liquid biopsy allows the identification of patients whose tumors harbor specific mutations in a minimally invasive manner. No prospective data have been available for the efficacy of osimertinib in patients with non-small cell lung cancer (NSCLC) who develop resistance to first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and who test positive for the...
Topics
Join the communities discussing this publication.